On 1 JULY STAAR Surgical Company (NASDAQ:STAA) announced that it has received CE Mark approval for its new Visian® ICL™ Preloaded System. The Preloaded ICL provides a number of benefits to both surgeons and their patients during the delivery of STAAR’s Implantable Collamer Lens (ICL) into the eye. STAAR plans the official launch of the Preloaded System at the Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in London during September 2014. STAAR Surgical Company (NASDAQ:STAA) net profit margin is -2.00% and weekly performance is -15.24%. On last trading day company shares ended up $13.85. Analysts mean target price for the company is $21.00. STAAR Surgical Company (NASDAQ:STAA) distance from 50-day simple moving average (SMA50) is -13.69%.
On 1 JULY OHR Pharmaceutical Inc (NASDAQ:OHRP) said that OHR Pharmaceutical Inc (NASDAQ:OHRP) Director Thomas M. Riedhammer acquired 6,900 shares of the stock on the open market in a transaction. The shares were purchased at an average cost of $7.39 per share, with a total value of $50,991.00. Following the purchase, the director now directly owns 124,667 shares of the company’s stock, valued at approximately $921,289. OHR Pharmaceutical Inc (NASDAQ:OHRP) shares fell -7.82% in last trading session and ended the day on $8.37. OHRP return on assets is -132.70%. OHR Pharmaceutical Inc (NASDAQ:OHRP) quarterly performance is -40.34%.
On 11 JUNE Five Prime Therapeutics Inc (NASDAQ:FPRX) announced that Aron Knickerbocker, Chief Business Officer of Five Prime, will present at the 2014 Wells Fargo Healthcare Conference. Five Prime Therapeutics Inc (NASDAQ:FPRX) shares moved down -5.21% in last trading session and was closed at $15.09, while trading in range of $14.82 – $15.78. Five Prime Therapeutics Inc (NASDAQ:FPRX) year to date (YTD) performance is -10.13%.
On 12 JUNE BIOLASE Inc (NASDAQ:BIOL) announced that it responds to clarify that this legal action is solely related to a false advertising and defamation suit filed by BIOLASE with the United States District Court in Orange County, California and does not affect the German Patent Infringement Suit won by BIOLASE in May awarding cash damages and injunctive relief. BIOLASE Inc (NASDAQ:BIOL) ended the last trading day at $2.06. Company weekly volatility is calculated as 8.87% and price to cash ratio as 43.08. BIOLASE Inc (NASDAQ:BIOL) showed a positive weekly performance of 6.19%.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) announced that Alder will be added to the Russell 3000® Index at the close of the market when Russell Investments reconstitutes its set of U.S. and global equity indexes. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) weekly performance is 2.72%. On last trading day company shares ended up $18.10. Analysts mean target price for the company is $25.33. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) distance from 50-day simple moving average (SMA50) is 27.18%.